RxDoctor Payments Data

Sumiyah Shaikh

Bridgeville, PANPI 1932816733

Payments from drug & device makers

$2,333in general payments, 2019–2025

Across 137 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$785
  • Alkermes, Inc.$428
  • Corium, LLC$359
  • Supernus Pharmaceuticals, Inc.$200
  • Johnson & Johnson$131
  • Ironshore Pharmaceuticals Inc.$70
  • plus $359 from 11 others

What the payments were for

  • Food & beverage$2,333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine34$841
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$736
Trazodone Hcl24$615
Venlafaxine Hcl ErVenlafaxine Hcl30$578
Clonazepam46$302
Lamotrigine18$268
Alprazolam19$229
Hydroxyzine Pamoate22$227
Quetiapine Fumarate11$220
Propranolol Hcl21$193
Gabapentin14$189
Duloxetine Hcl21$159
Buspirone Hcl25$138
Amitriptyline Hcl22$130
Clonidine Hcl26$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$44$5514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →